Precision oncology begins with access - to the right data, at the right time, in the right context. At Genomenon, we recognize the critical role that high-quality genomic insights play in identifying oncogenic drivers and guiding treatment decisions. That’s why we offer free, ongoing access to expertly curated variant data for a set of 50 cancer-relevant genes through our Cancer Knowledgebase (CKB).
These genes are rotated each quarter and are not selected at random - they represent some of the most clinically significant and therapeutically actionable targets across both solid tumors and hematologic malignancies. This quarter we are also providing 14 genes that encode tyrosine kinases, which are central to oncogenic signaling.
By combining scientific literature, drug associations, and clinical trial data - each reviewed and curated by experts - CKB delivers a comprehensive and trusted resource for real-world oncology decision-making.
Anchored in Evidence, Aligned with Progress : What Our Genes Cover
CKB CORE is designed around a dual-tier model that gives users both stability and adaptability:
- 36 Core Oncology Genes, available year-round, represent the molecular backbone of cancer interpretation. These genes - like TP53, BRAF, IDH1, PIK3CA, and JAK2 - are frequently mutated across tumor types and deeply tied to cancer onset, progression, and resistance.
- 14 Thematic Genes, updated quarterly, spotlight emerging trends in oncology - whether it’s new therapeutic targets, drug approvals, or areas of heightened regulatory interest.
Together, these 50 curated genes serve as a powerful foundation for diagnostics, interpretation, and therapeutic development.
But for those seeking complete coverage, the full power of CKB lies in its CKB BOOST offer:
Over 2,100 expertly curated genes, each with deep, literature-backed variant annotations, therapeutic relevance, and clinical trial evidence. BOOST unlocks the full depth of our curation engine - across every tumor type, pathway, and biomarker of interest.
This Quarter’s Theme: Tyrosine Kinase Genes
Tyrosine kinases are central to oncogenic signaling. When mutated or overexpressed, these genes can drive uncontrolled growth, metastasis, and drug resistance. Many are also direct therapeutic targets - with FDA-approved inhibitors or active clinical trials.
This quarter, we’re offering free access to the following 14 tyrosine kinase genes:
ABL1, AXL, BTK, CSF1R, ERBB3, ERBB4, JAK1, KDR, MERTK, MST1R, NTRK1, NTRK2, PDGFRB, SRC, TYRO3
These are offered in addition to key tyrosine kinase genes that are always available in the full CKB database, including: FLT3, KIT, FGFR1, FGFR2, FGFR3, ALK, ROS1, RET, JAK2, and JAK3.
Whether you're tracking resistance variants, selecting patients for clinical trials, or validating panel content, this targeted set helps you stay aligned with the fast-moving world of kinase-targeted therapies.
Where Insight Meets Action: CKB in the Oncology Workflow
Access to expertly curated variant data can transform how oncology professionals interpret results, make decisions, and develop therapies. CKB was built with this real-world impact in mind - serving the distinct needs of clinical labs, researchers, and pharmaceutical teams alike.
For clinical laboratories, CKB accelerates variant interpretation by offering immediate access to literature-backed insights on drug sensitivity, resistance mechanisms, and clinically observed variants. This streamlines workflows, enhances reporting accuracy, and supports more confident, evidence-driven decisions in patient care.
For researchers, CKB removes the burden of manual literature searching by providing a clear and structured view of the variant landscape across high-impact cancer genes. Functional and pathogenic variants are contextualized with relevant data, enabling teams to generate hypotheses, prioritize targets, and design experiments grounded in real-world evidence.
For pharmaceutical and biotech teams, CKB delivers critical support for biomarker discovery, drug development, and trial design. Curated information on druggable variants, resistance patterns, and co-occurring variants empowers teams to identify opportunities, refine therapeutic strategies, and assess competitive landscapes with confidence.
And while the free 50-gene model delivers essential insight, CKB BOOST takes it further, offering the breadth and depth needed to drive discovery, refine strategy, and move therapeutics forward.
Conclusion
Precision oncology isn’t just about sequencing - it’s about making sense of what we find, with evidence that is comprehensive, current, and clinically actionable.
At Genomenon, we support this mission by providing expertly curated variant insights for 50 high-impact cancer genes - empowering researchers, clinicians, and developers to advance evidence-based care.
But cancer is not one disease - it’s a complex, ever-evolving landscape. Real progress demands a broader view.
That’s where CKB BOOST comes in.
BOOST extends your reach to over 2,100 expertly curated genes and 48,000 variants - covering major tumor types, therapeutic areas, and emerging targets. From common biomarkers to rare variants, it delivers the complete picture for confident, high-impact decision-making.
Because in oncology, having the right variant data isn’t just helpful - it’s essential.
